Back to Journals » Therapeutics and Clinical Risk Management » Volume 11

Treatment of adult-onset Still’s disease: a review

Authors Jamilloux Y, Gerfaud-Valentin M, Henry T, Sève P

Received 3 October 2014

Accepted for publication 13 November 2014

Published 22 December 2014 Volume 2015:11 Pages 33—43

DOI https://doi.org/10.2147/TCRM.S64951

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Professor Garry Walsh

Yvan Jamilloux,1–3,* Mathieu Gerfaud-Valentin,1,* Thomas Henry,3 Pascal Sève1

1Department of Internal Medicine, Hôpital de la Croix-Rousse, Université Claude Bernard-Lyon 1, Lyon, France; 2Department of Biochemistry, University of Lausanne, Epalinges, Switzerland; 3International Research Center on Infectiology. INSERM U1111. Université Claude Bernard-Lyon 1, Lyon, France

*These authors contributed equally to this work

Abstract: Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder that has been recently classified as a polygenic autoinflammatory disorder. The former classification, based on the disease course, seems to be quite dated. Indeed, there is accumulating evidence that AOSD can be divided into two distinct phenotypes based on cytokine profile, clinical presentation, and outcome, ie, a “systemic” pattern and an “articular” pattern. The first part of this review deals with the treatments that are currently available for AOSD. We then present the different strategies based on the characteristics of the disease according to clinical presentation. To do so, we focus on the two subsets of the disease. Finally, we discuss the management of life-threatening complications of AOSD, along with the therapeutic options during pregnancy.

Keywords: adult-onset Still’s disease, treatment, anakinra, tocilizumab, canakinumab


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]